published meta-analysis   sensitivity analysis   studies

peginterferon in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias hospitalizationdetailed resultsJagannathan, 2020 1.00 [0.14; 7.34] 1.00[0.14; 7.34]Jagannathan, 202010%120NAnot evaluable viral clearance detailed resultsJagannathan, 2020 0.81 [0.56; 1.18] 0.81[0.56; 1.18]Jagannathan, 202010%120NAnot evaluable viral clearance (time to event analysis only)detailed resultsJagannathan, 2020 0.81 [0.56; 1.18] 0.81[0.56; 1.18]Jagannathan, 202010%120NAnot evaluable serious adverse eventsdetailed resultsJagannathan, 2020 1.00 [0.14; 7.34] 1.00[0.14; 7.34]Jagannathan, 202010%120NAnot evaluable adverse eventsdetailed resultsJagannathan, 2020 1.33 [0.63; 2.78] 1.33[0.63; 2.78]Jagannathan, 202010%120NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:58 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 883 - roots T: 290